Partners

Stem Cell Innovations offers commercial partners access to its high-end human cell technologies and expertise through fee-for-service activities, collaborative partnerships and selective out-licensing. In addition, SCI is interested in exploring research alliances with academic and industrial partners as well as patient foundations in several therapeutic areas.

Current partners include:

• ALS Association
• BioFocus DPI, a Galapagos company
• Massachusetts Eye and Ear Infirmary, Harvard Medical School
• Stanford University
• Twente University
• Leiden University Medical Center

Academic Program:

Stem Cell Innovations is interested in partnering with academic organizations involved in disease based research in particular neurodegenerative disorders. SCI is seeking to make its PluriCells available to universities and other not-for-profit institutions under a Material Transfer Agreement to rapidly advance the potential benefits which easily-scalable human stem cells can have as disease treatments and drug development tools.

For more information contact:
Ivo Piest (Senior Director Business & Corporate Development), piest@stemcellinnovations.com